Published in Antimicrob Agents Chemother on August 01, 2005
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Resistance to echinocandin-class antifungal drugs. Drug Resist Updat (2007) 4.63
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol (2007) 3.57
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother (2006) 3.19
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother (2009) 3.13
Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother (2008) 3.05
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 2.54
A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics (2006) 2.54
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol (2006) 2.53
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother (2008) 2.44
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother (2008) 2.41
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother (2009) 2.41
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother (2006) 2.37
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother (2006) 2.22
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother (2007) 2.20
Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog (2008) 2.19
Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother (2007) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother (2008) 2.13
Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother (2005) 2.08
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol (2006) 2.00
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother (2010) 1.88
Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis (2014) 1.86
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother (2010) 1.79
Fungal echinocandin resistance. Fungal Genet Biol (2009) 1.78
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother (2010) 1.68
Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet Biol (2008) 1.67
Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog (2011) 1.53
Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother (2008) 1.46
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother (2012) 1.44
Current perspectives on echinocandin class drugs. Future Microbiol (2011) 1.44
A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.44
Antifungal resistance and new strategies to control fungal infections. Int J Microbiol (2011) 1.44
Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother (2011) 1.39
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother (2014) 1.38
Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother (2008) 1.38
Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother (2006) 1.35
Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol (2008) 1.29
Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicans. Antimicrob Agents Chemother (2010) 1.26
Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother (2006) 1.25
Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother (2011) 1.25
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother (2011) 1.25
Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.22
Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother (2011) 1.21
Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis (2009) 1.20
Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2009) 1.19
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother (2012) 1.13
Mechanisms of Candida biofilm drug resistance. Future Microbiol (2013) 1.13
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol (2008) 1.13
Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother (2012) 1.11
Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother (2011) 1.10
Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother (2011) 1.07
Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother (2012) 1.06
Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother (2011) 1.04
FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother (2010) 1.01
Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother (2010) 0.99
Emerging Threats in Antifungal-Resistant Fungal Pathogens. Front Med (Lausanne) (2016) 0.98
Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother (2009) 0.98
In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc (2008) 0.97
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother (2011) 0.97
Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata. J Clin Microbiol (2013) 0.97
Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int (2013) 0.97
RNA sequencing revealed novel actors of the acquisition of drug resistance in Candida albicans. BMC Genomics (2012) 0.96
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother (2006) 0.93
Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother (2011) 0.93
Echinocandin Resistance in Candida. Clin Infect Dis (2015) 0.93
Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res (2011) 0.92
Differential activities of three families of specific beta(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeast. J Biol Chem (2010) 0.92
CD101: a novel long-acting echinocandin. Cell Microbiol (2016) 0.91
Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother (2012) 0.91
Genetic Basis of Antifungal Drug Resistance. Curr Fungal Infect Rep (2009) 0.90
Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob Agents Chemother (2014) 0.90
Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J Antimicrob Chemother (2008) 0.90
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol (2011) 0.88
Update on Antifungal Drug Resistance. Curr Clin Microbiol Rep (2015) 0.87
Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. Antimicrob Agents Chemother (2014) 0.87
Echinocandin resistance in Candida spp. isolated from liver transplant recipients. Antimicrob Agents Chemother (2016) 0.87
Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei. Antimicrob Agents Chemother (2014) 0.86
Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob Agents Chemother (2012) 0.86
Nanoscale effects of caspofungin against two yeast species, Saccharomyces cerevisiae and Candida albicans. Antimicrob Agents Chemother (2013) 0.85
Mutants in the Candida glabrata glycerol channels are sensitized to cell wall stress. Eukaryot Cell (2012) 0.84
Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance. Med Mycol (2008) 0.83
Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy. Antimicrob Agents Chemother (2015) 0.80
Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates. Med Mycol (2013) 0.80
Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy. Antimicrob Agents Chemother (2015) 0.80
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. Antimicrob Agents Chemother (2016) 0.79
Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors. Antimicrob Agents Chemother (2014) 0.79
Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther (2009) 0.78
Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci (2010) 0.77
An automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target Candida albicans virulence-related proteins. PLoS One (2014) 0.77
Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr. Antimicrob Agents Chemother (2014) 0.77
Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis. PLoS Genet (2016) 0.76
New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study. BMC Infect Dis (2015) 0.76
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infect Drug Resist (2009) 0.76
Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics (1943) 165.64
New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene (1988) 42.65
Isogenic strain construction and gene mapping in Candida albicans. Genetics (1993) 17.18
Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med (2002) 9.21
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
A rapid method for localized mutagenesis of yeast genes. Yeast (1992) 7.79
A simple and efficient procedure for transformation of yeasts. Biotechniques (1992) 6.08
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 5.76
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A (1994) 3.90
Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem (1994) 3.52
Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun (1996) 3.08
Caspofungin. Clin Infect Dis (2003) 3.03
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis (1998) 2.96
Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother (2004) 2.96
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother (2003) 2.92
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol (2003) 2.89
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother (2000) 2.51
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother (1995) 2.37
A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol (1994) 2.33
Fungal beta(1,3)-D-glucan synthesis. Med Mycol (2001) 2.30
Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol (1997) 2.01
Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein. J Bacteriol (1996) 1.82
An improved protocol for the preparation of yeast cells for transformation by electroporation. Yeast (1998) 1.75
Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol (2003) 1.75
Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother (2003) 1.71
Caspofungin: an echinocandin antifungal agent. Clin Ther (2002) 1.71
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol (2002) 1.64
The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol (2003) 1.59
Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs (2001) 1.48
Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae. Antimicrob Agents Chemother (1995) 1.38
Multilocus sequence typing is a reliable alternative method to DNA fingerprinting for discriminating among strains of Candida albicans. J Clin Microbiol (2004) 1.33
FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-beta-glucan synthase inhibitor arborcandin C. Antimicrob Agents Chemother (2004) 1.15
Cloning of the RHO1 gene from Candida albicans and its regulation of beta-1,3-glucan synthesis. J Bacteriol (1997) 1.09
The echinocandin "target" identified by cross-linking is a homolog of Pil1 and Lsp1, sphingolipid-dependent regulators of cell wall integrity signaling. Antimicrob Agents Chemother (2004) 1.02
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J Cell Biol (1999) 8.07
Cultivation of Borrelia hermsi. Science (1971) 6.83
Comparison of sequence profiles. Strategies for structural predictions using sequence information. Protein Sci (2000) 6.23
RNA metabolism of murine leukemia virus: detection of virus-specific RNA sequences in infected and uninfected cells and identification of virus-specific messenger RNA. J Mol Biol (1973) 6.19
Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol (2000) 5.99
Stem cell properties of human dental pulp stem cells. J Dent Res (2002) 5.57
A hyper-recombination mutation in S. cerevisiae identifies a novel eukaryotic topoisomerase. Cell (1989) 5.52
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS (2000) 5.14
Identification of the gene responsible for Best macular dystrophy. Nat Genet (1998) 4.89
Measurement of the sequence complexity of cloned Moloney murine leukemia virus 60 to 70S RNA: evidence for a haploid genome. J Virol (1974) 4.84
Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells. Nature (1984) 4.52
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J (2001) 4.40
Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and estimated-diet records. Br J Nutr (1994) 4.32
How valid are medical records and patient questionnaires for physician profiling and health services research? A comparison with direct observation of patients visits. Med Care (1998) 4.16
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
In vitro synthesis of DNA complementary to rabbit reticulocyte 10S RNA. Nat New Biol (1972) 4.01
Regulation of protein synthesis in mammalian cells. II. Inhibition of protein synthesis at the level of initiation during mitosis. J Mol Biol (1970) 3.98
The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A (1994) 3.90
High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun (2006) 3.86
Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. Int J Epidemiol (1997) 3.79
A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS (1998) 3.54
A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet (2001) 3.52
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat (2011) 3.40
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37
A preliminary report comparing magnetic resonance coronary angiography with conventional angiography. N Engl J Med (1993) 3.32
The rate of nuclear cytoplasmic protein transport is determined by the casein kinase II site flanking the nuclear localization sequence of the SV40 T-antigen. EMBO J (1991) 3.27
Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature (1992) 3.13
A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol (1991) 3.13
Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun (1996) 3.08
Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature (1992) 3.02
Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg (1977) 3.02
Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr (1999) 3.01
CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. J Clin Invest (1998) 2.74
Directed mutagenesis in Candida albicans: one-step gene disruption to isolate ura3 mutants. Mol Cell Biol (1987) 2.71
Jaagsiekte sheep retrovirus is necessary and sufficient to induce a contagious lung cancer in sheep. J Virol (1999) 2.70
gag-Related polyproteins of Moloney murine leukemia virus: evidence for independent synthesis of glycosylated and unglycosylated forms. J Virol (1979) 2.68
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal. Proc Natl Acad Sci U S A (1975) 2.64
Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology (1992) 2.63
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother (2002) 2.60
Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol (1997) 2.58
Pleiotropic plasma membrane ATPase mutations of Saccharomyces cerevisiae. Mol Cell Biol (1987) 2.54
Learning to see: experience and attention in primary visual cortex. Nat Neurosci (2001) 2.53
Rechargeable lithium batteries with aqueous electrolytes. Science (1994) 2.53
Contribution of increasing CO2 and climate to carbon storage by ecosystems in the United States. Science (2000) 2.51
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol (1999) 2.48
Mouse DNA 'fingerprints': analysis of chromosome localization and germ-line stability of hypervariable loci in recombinant inbred strains. Nucleic Acids Res (1987) 2.47
The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun (2005) 2.47
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother (1998) 2.44
Selection of children to provide care: the effect of earlier parental transfers. J Gerontol B Psychol Sci Soc Sci (1997) 2.43
Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. Am J Gastroenterol (1993) 2.42
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother (1992) 2.39
Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells. Proc Natl Acad Sci U S A (1993) 2.39
A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol (1994) 2.33
Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast. Nature (1992) 2.32
Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ (1997) 2.31
PDF receptor signaling in Drosophila contributes to both circadian and geotactic behaviors. Neuron (2005) 2.30
The cellular C1 factor of the herpes simplex virus enhancer complex is a family of polypeptides. J Biol Chem (1995) 2.27
Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A (1995) 2.27
Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology (2000) 2.24
Differential activation of Myf5 and MyoD by different Wnts in explants of mouse paraxial mesoderm and the later activation of myogenesis in the absence of Myf5. Development (1998) 2.22
Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci U S A (1995) 2.17
In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol (1993) 2.15
DNA topoisomerase IIbeta and neural development. Science (2000) 2.14
A new iterative procedure for combining direct methods with solvent flattening - dealing with the phase ambiguity in protein crystallography. Acta Crystallogr D Biol Crystallogr (1997) 2.12
Quantitation of "acute-phase proteins" postoperatively. Value in detection and monitoring of complications. Am J Clin Pathol (1976) 2.11
Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambda. J Virol (1980) 2.10
Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem (2001) 2.09
Feature (gene) selection in gene expression-based tumor classification. Mol Genet Metab (2001) 2.08
Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation (2000) 2.07
Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16. J Med Genet (2007) 2.06
Suppression of leukaemia virus pathogenicity by polyoma virus enhancers. Nature (1985) 2.03
Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J Antibiot (Tokyo) (1992) 2.02
Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc Natl Acad Sci U S A (2001) 2.01
Virus-like 30S RNA in mouse cells. J Virol (1979) 1.99
Low-multiplicity infection of Moloney murine leukemia virus in mouse cells: effect on number of viral DNA copies and virus production in producer cells. J Virol (1978) 1.99
Identification and molecular cloning of Moloney mouse sarcoma virus-specific sequences from uninfected mouse cells. Proc Natl Acad Sci U S A (1980) 1.98
Multiple sclerosis in southern Europe. I: Prevalence in Sicily in 1975. J Epidemiol Community Health (1979) 1.98
Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. Nat Med (1996) 1.97
Defining the minimum level of detectable change for the Roland-Morris questionnaire. Phys Ther (1996) 1.97
Prospective comparison treatment of 595-nm pulsed-dye lasers for virgin port-wine stain. Br J Dermatol (2015) 1.96
Monospecific immunoprecipitation of murine leukemia virus polyribosomes: identification of p30 protein-specific messenger RNA. Cell (1976) 1.94
VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res (1999) 1.91
Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor. Mol Cell Biol (1993) 1.91
Size analysis and relationship of murine leukemia virus-specific mRNA's: evidence for transposition of sequences during synthesis and processing of subgenomic mRNA. J Virol (1978) 1.90
Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med (1997) 1.89
Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem (1999) 1.88
Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res (2001) 1.87
Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem (1993) 1.86
Two blocks in Moloney murine leukemia virus expression in undifferentiated F9 embryonal carcinoma cells as determined by transient expression assays. J Virol (1989) 1.84